Common Ground: Both studies focus on Parkinson’s disease (PD), examining treatments to mitigate neurodegenerative damage and inflammation, particularly affecting α-synuclein and inflammatory markers.
Key Differences: The current study investigates the effects of GABA on MAPK signaling in neuronal cells and mouse models, while the recommended study examines Lactobacillus sakei (Ls) orally administered to affect the gut-brain axis in PD mouse models.
Methodologies: The current study uses MPTP-induced SH-SY5Y cells and PD model mice treated with GABA, including biomarker analysis and behavioral tests. The recommended study employs oral administration of probiotics to PD model mice, with analysis of microbial composition, mRNA/protein levels, and molecular pathways.
Complementary Aspects: The current study provides neuroprotective and anti-inflammatory insights through GABA's action on signaling pathways. The recommended study offers a broader perspective on the gut microbiome and systemic effects, including intestinal and blood-brain barriers.
Potential Impact: Integrating both studies could elucidate comprehensive mechanisms linking gut-brain axis interventions and neuroprotective treatments for PD.

Scheduled maintenance in progress.